#Novamind news update#

Scheduled to open between July and September 2021, the New Clinics represent the initial phase of Novamind's national expansion strategy whereby the Company is replicating the successful operating track record of its current clinics in Utah, at scale, ahead of its expansion into other American states in 2021. Novamind has begun construction on three of the New Clinics and leased a fourth additional property. The expanded capacity from the New Clinics is forecasted to increase Novamind's patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021, a 325% increase. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics (the 'New Clinics'), doubling its network to eight total locations. TORONTO, ON / ACCESSWIRE / / Novamind Inc.

#Novamind news update#

The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.New clinics represent the first phase of Novamind's national expansion strategy

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. Samantha DeLenardo, VP, Communications Email: Mitoulas, Investor Relations Email: Statements Novamind Yaron Conforti, CEO and Director Telephone: +1 (647) 953 9512 For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind.

Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. A short Q&A session will follow.įor more information about the event and to register for free, visit: About Novamind Conforti will deliver a presentation to update investors on the Company’s rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. Novamind’s CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, “ Addressing Mental Health through Emerging Therapies” on Thursday, September 30 at 12:35 PM EST.įollowing the panel, from 1:15 PM to 1:30 PM EST, Mr. This advertisement has not loaded yet, but your article continues below.